ImmuneHonlutenEDG

Chonluten (EDG)

Khavinson 'Cytogen' synthetic tripeptide · marketed as a lung/respiratory bioregulator · single in-vitro immune study, claims unproven

Chonluten (also spelled Honluten) is a synthetic tripeptide — Glu-Asp-Gly (EDG) — from the 'Cytogen' line of short 'peptide bioregulators' developed by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It is sold as the 'respiratory' or 'lung' peptide, marketed to regenerate lung tissue and support conditions like COPD, asthma and bronchitis. Two things make this one tricky. First, the molecule itself is verifiable — Glu-Asp-Gly is a real, well-defined tripeptide in the chemical database — but the name 'Chonluten' is not a chemical-database name, and the same brand is sold both as a tissue extract (oral) and as the synthetic tripeptide (injectable), with the synthetic molecule's identity quietly attached to both. Second, the evidence is extremely thin: there is essentially one peer-reviewed study, and it is an in-vitro experiment from Khavinson's own network in which Chonluten was just one of five peptides showing a generic anti-inflammatory effect in a lab dish of immune cells — nothing to do with lungs, and not a human trial. Stranger still, the molecule's own scientific literature describes a stress-protective, brain-related effect, not a respiratory one. The honest framing: a real little tripeptide with a single, narrow, anti-inflammatory immune data point — and a respiratory marketing story that has no science behind it.

The short version

Chonluten (sometimes spelled Honluten) is a trade name for EDG, a synthetic peptide of three amino acids (glutamic acid, aspartic acid, glycine). It belongs to a Russian family of tiny 'bioregulator' peptides designed by Vladimir Khavinson's group, where each peptide is assigned a target organ. Chonluten's assigned organ is the lungs, and it is marketed for respiratory health.

The molecule is real — the tripeptide Glu-Asp-Gly is well-defined in the chemical database. But two things should make you cautious. The name 'Chonluten' itself isn't found in chemistry databases (only the underlying tripeptide is), and the same brand is sold both as a tissue extract you take by mouth and as the synthetic peptide in a vial — different substances under one label.

The bigger issue is the evidence. There is basically one peer-reviewed study, done in a lab dish by Khavinson's own group, where Chonluten was one of five peptides that reduced inflammation markers in immune cells. That is interesting but narrow — it is not a lung study, not an animal study of breathing, and not a human trial. In fact, the molecule's own published science describes a stress-protective, brain-related effect, not a respiratory one. So the claims that Chonluten regenerates lung tissue or treats COPD, asthma or bronchitis are not backed by any study of Chonluten in the lungs. Treat it as an experimental peptide with one narrow immune data point and a respiratory story that the science doesn't support.

Molecular identity

Specs

Molecular formula: C₁₁H₁₇N₃O₈
Molecular weight: 319.27 g/mol
Monoisotopic mass: 319.1016 Da

Sequence (3 AA): Glu-Asp-Gly (EDG) — H-Glu-Asp-Gly-OH, all-LPubChem CID 194641 (synonym 'T-34 tripeptide')
Structure / class: Synthetic tripeptide; Khavinson 'Cytogen' bioregulator (also sold as a bronchial/lung tissue extract — see note)PubChem CID 194641; Khavinson-school literature
PubChem CID: 194641 (as 'glutamyl-aspartyl-glycine' / 'T-34 tripeptide')PubChem — note: 'Chonluten' is NOT a PubChem synonym; the trade-name link is vendor/single-school
InChIKey: DSPQRJXOIXHOHK-WDSKDSINSA-NPubChem CID 194641 (defined L-config stereo layer)
CAS / UNII: 75007-24-8 · UNII not assignedPubChem CID 194641 synonyms (CAS present; no UNII in record)
Water solubility: Freely water-soluble (small, highly polar free-acid tripeptide; reconstituted in bacteriostatic water)Structural inference (ionizable Glu/Asp side chains)
Molecular target: No classic receptor identified; claimed gene-expression modulator. Vendor positioning is respiratory/lung; the one confirmed study is a monocyte anti-inflammatory (TNF/IL-6) readout, not respiratoryVendor marketing vs. PMID 35408963
Half-life: Not established (no published human pharmacokinetics)Not established
Regulatory status: Not approved by any major drug regulator; no controlled human trials locatedNo NDA/BLA/EMA record located

Plain English

Mechanism

The Khavinson school proposes that ultra-short peptides like EDG act as direct 'epigenetic' gene regulators — the peptide enters the cell, reaches the nucleus, binds specific DNA or chromatin regions, and turns target genes up or down. For Chonluten the marketed mechanism is respiratory tissue repair, but the one thing actually demonstrated is different and narrow: in cultured human monocyte/macrophage cells (THP-1 line), Chonluten — alongside four other Khavinson peptides — reduced the inflammatory signals TNF and IL-6 after an LPS-triggered inflammatory stimulus. That is a generic anti-inflammatory readout in immune cells — not a lung-regeneration mechanism.

It must be said plainly that this 'short peptide = direct epigenetic gene regulator' model is a single-school hypothesis, never independently validated outside the Khavinson network. And separately, the defined EDG molecule's own chemistry/patent literature describes a 'stress-protective' effect on the brain (modulating biogenic amines, c-fos, enkephalinase) — a central-nervous-system framing, not a respiratory one. The same molecule therefore appears under two different functional stories, and vendors do not disclose this.

So the honest mechanistic picture is: an unproven gene-regulation hypothesis; one in-vitro anti-inflammatory finding in immune cells (a monocyte TNF/IL-6 panel); and a separate, CNS-flavoured story in the molecule's own literature — none of which establishes the lung-regeneration mechanism the marketing claims.

Sources:PMID 35408963

Why people reach for it

Potential benefits

Chonluten is the 'lung' peptide of the Khavinson Cytogen line — here is what draws people to it, kept honest about a single in-vitro data point and a respiratory marketing story the science doesn't support.

The respiratory slot in a Khavinson routine — Chonluten is the line's lung/bronchi-assigned tripeptide, so people building a tissue-by-tissue bioregulator protocol reach for it as the respiratory piece — a marketing position, not a demonstrated lung effect.
One genuine anti-inflammatory data point — Its single confirmed study found it lowered the inflammatory signals TNF and IL-6 in cultured immune cells — a narrow, in-vitro, immune (not respiratory) finding, which is the one real research hook it has.
A genuinely well-defined little molecule — Unlike some products in this family, the underlying EDG (Glu-Asp-Gly) tripeptide is a real, chemically verifiable molecule — part of the appeal is that you at least know what the synthetic form is, even if its claims are unproven.
Short, low-burden, course-based — Run as brief pulsed courses with a long washout rather than continuous use, it asks little of the user — appealing to people already invested in the Khavinson approach.

Sources:PMID 35408963

What people reach for Chonluten for, drawn from its positioning and the single confirmed study (an in-vitro immune readout) — not proven human outcomes or medical claims. The marketed respiratory effects have no supporting study, and this is not a treatment for COPD, asthma, or any condition.

Implied timing

Best time to dose

Implied best time

Anytime (consistent)

Time of day isn't critical for Chonluten — pick a consistent daily time within the course and hold it.

Chonluten has no published human pharmacokinetics and no half-life on record, so there is no clearance curve to time a dose against — day-to-day consistency matters more than the exact hour.
Its one confirmed effect is a generic anti-inflammatory signal in immune cells, with no circadian dimension shown — nothing in the evidence points to a better or worse time of day.
If it is run alongside other short-peptide bioregulators, fixing it to the same daily slot (spacing injections for comfort and site rotation) is the simplest way to keep the course consistent.

No study establishes an ideal time of day for Chonluten — this is reasoned from its mechanism and how it's used, not from data. As a rule of thumb most peptide dosing lands in the midday-to-evening window; for Chonluten any consistent time is equally defensible.

Sources:PMID 35408963

How to run it

Dosing & protocol

Chonluten is dosed here as a subcutaneous injection — the synthetic-peptide form sold in research vials and the route the on-page calculator is built for. There is no published human dose anywhere: no human trial exists, so the amounts and schedule below are convention drawn from the Khavinson school's own published course patterns and from broader research-peptide community practice. Read this as a map of how people actually run injectable Chonluten — not a validated prescription.

Convention only, not trial-proven: Chonluten has zero human trials and no established human dose, and it is not approved by any drug regulator. Its one confirmed study is an in-vitro immune-cell experiment; subcutaneous use for any goal is extrapolated from mechanism, not demonstrated in a trial. Every number here is a usage pattern, not evidence.

Dose — no established human dose

No controlled trial has set a human dose. The ranges below follow the Khavinson school's general short-peptide convention and community practice.

Convention range:: 500–1,000 mcg per injection, once daily — the range most cited in Khavinson-school protocols for short bioregulator peptides of this size.
Route:: Subcutaneous injection, same as other research peptides in this class. The extract form (oral/sublingual) sold under the same name is a different product and is not what the calculator or this section addresses.
Frequency:: Once daily during a pulsed course (see Cycle card below). Splitting across the day is not reported in convention for this compound.

Subcutaneous administration

Inject into subcutaneous fat — the actionable choices are site, rotation, and timing.

Injection site:: The abdomen (staying a couple of inches clear of the navel), the love-handle area, or the outer thigh. Rotate sites between doses — prevents local irritation and fatty-tissue accumulation at any one spot.
Measuring the dose:: Drawn on a U-100 insulin syringe from the reconstituted vial. At the standard 2 mL BAC reconstitution (5,000 mcg/mL): 500 mcg = 10 IU · 750 mcg = 15 IU · 1,000 mcg = 20 IU. The on-page calculator handles any vial size.
Time of day:: Time of day isn't critical for Chonluten — see Best time to dose above. A consistent daily time matters more than the exact hour; if stacking, separate the dose from any other peptide injections by at least 30 minutes for comfort and site rotation.
Food window:: Subcutaneous injection does not compete with food for absorption; timing relative to meals is not reported as meaningful for this compound.

Cycle & washout

The Khavinson school uses short, pulsed courses — this is a defining feature of the bioregulator framework, not a general peptide convention.

Course length:: ~10 days of consecutive daily injections — the canonical Khavinson bioregulator course. Some community protocols extend to 14 days.
Washout:: A break of at least 4–6 months before repeating, per the Khavinson school's recommended seasonal or twice-yearly pattern. This is far longer than the washouts of most other research peptides.
Rationale:: The school's theory is that short-peptide bioregulators trigger a self-sustaining gene-expression change that does not require continuous dosing — hence the short course and long gap. This mechanism hypothesis is single-school and unproven; the long washout is the practice, whatever the reason.

Reconstitution at a glance

The on-page calculator does this live; the quick reference for the standard 10 mg vial + 2 mL BAC default:

Mixing:: 10 mg vial + 2 mL bacteriostatic water = 5,000 mcg per mL. On a 100-unit (1 mL) insulin syringe: 500 mcg = 10 IU · 750 mcg = 15 IU · 1,000 mcg = 20 IU.
Why 2 mL:: The tighter dilution keeps syringe unit increments manageable for this dose range — smaller volumes with more concentrated peptide reduce draw-volume errors at the low end.

Sources:PMID 35408963

Substrate the signal needs

Nutritional cofactor precision

The only confirmed thing Chonluten does is reduce TNF and IL-6 in stimulated immune cells — an anti-inflammatory signal in a monocyte line. That is the anchor for the cofactors below. The approach: amplify the immune-modulating signal with nutrients that run the same brake on inflammatory cytokine output; supply the substrate those cells need to function. The marketed respiratory story has no confirmed Chonluten data, so no respiratory-specific cofactor logic is built here — that would be reasoning on a claim, not on evidence.

Reasoned from the one confirmed anti-inflammatory immune readout (PMID 35408963) plus general immune-nutrition science — not a Chonluten cofactor study. Supplement doses are community ranges, not Chonluten-specific findings. The single-school gene-regulation hypothesis is unproven.

Zinc + Selenium + Vitamin D (amplify the immune brake)

The three nutrients most directly tied to the anti-inflammatory cytokine regulation Chonluten's one data point sits in.

Zinc 15–30 mg:: Zinc is a natural brake on NF-κB — the same transcription factor that drives TNF and IL-6 production the in-vitro study measured. A deficiency lets inflammatory signaling run hotter; repleting it supports the same direction. Zinc picolinate or bisglycinate daily with food. Above 40 mg/day sustained, pair with 1–2 mg copper bisglycinate to prevent depletion.
Selenium 100–200 mcg:: Selenium supports glutathione peroxidase and thioredoxin reductase — the redox enzymes that dampen oxidative-stress-driven inflammatory signaling in macrophages, the same cell type tested. Selenomethionine or selenocysteine preferred; Brazil nuts are variable. Stay under 400 mcg/day (toxicity threshold).
Vitamin D 2,000–5,000 IU:: Vitamin D receptors are expressed throughout the immune system; deficiency is independently associated with elevated inflammatory cytokine baseline. Dose to achieve a blood level in the sufficient range (50–80 ng/mL) — the IU needed to get there varies; get a level first. Taken with the fattiest meal of the day for absorption.

Protein + Vitamin C + Omega-3 (supply the substrate)

What the immune cells running the anti-inflammatory response actually consume — the supply side.

Protein 1.6–2.0 g/kg body weight:: Amino acids are the raw material for every immune cell synthesized. Monocytes and macrophages turn over rapidly; dietary protein below threshold leaves fewer resources for immune housekeeping. Spread across 3–4 meals for sustained availability.
Vitamin C 500–1,000 mg:: Vitamin C accumulates in immune cells at concentrations many times higher than plasma — it is an active participant in macrophage function, not just an antioxidant bystander. Split dose (morning + evening) as it clears in ~4 hours. Buffered or liposomal forms reduce gut intolerance at higher amounts.
Omega-3 (EPA/DHA) 2–3 g combined:: EPA and DHA compete with arachidonic acid for the same inflammatory-signaling enzymes (COX/LOX), shifting the balance toward less-inflammatory eicosanoids and dampening macrophage TNF/IL-6 output — the exact readout the study measured. Taken with the fattiest meal.

Combinations + timing

Stacking notes + timing windows

Chonluten's stacking options are narrow by design — it has one confirmed data point (immune-cell anti-inflammation) and a disputed identity. The most honest pairings are (a) within the Khavinson bioregulator family, where users combine multiple short peptides on the school's one-peptide-per-organ logic, or (b) with a complementary immune-modulating peptide from better-established evidence. Both pairings carry explicit caveats.

Combinations reasoned from complementary mechanisms — Chonluten itself has no human trial, so any stack is doubly unproven. Stacking multiple Khavinson bioregulators multiplies single-school speculation rather than reducing it. Doses are community convention; 'reached for' describes user practice, not a proven indication.

Khavinson Bioregulator Family (Epithalon · Thymalin / Thymulin)

The community combination within the school's framework — flag: this multiplies speculation, not evidence.

Why it works (in theory):: The Khavinson one-peptide-per-organ model assigns Chonluten to the lungs/bronchi, Epithalon to the pineal/aging axis, and Thymalin/Thymulin-class peptides to the thymus and immune system. Users combine them on the logic that each operates on a different tissue, so there is no lever duplication. Within the school's own framework this is internally consistent.
The protocol:: The standard Khavinson bioregulator course: each peptide run on its own consecutive-day cycle (~10 days each), typically sequenced one after the other rather than co-injected, at individual doses per the convention ranges. Epithalon is often run first or separately on its longer published course.
Outcome:: Reached for by users committed to the full Khavinson bioregulator protocol as an anti-aging / organ-support system. The critical flag: every peptide in this combination sits on the same single-school, unvalidated foundation as Chonluten itself — combining them multiplies the speculation, not the evidence. No trial has tested any Khavinson peptide combination.

Chonluten + Thymosin Alpha-1

The more defensible immune pairing — better evidence base, complementary mechanism. Thymosin Alpha-1 link.

Why it works:: Chonluten's one confirmed finding is a reduction of pro-inflammatory cytokines (TNF/IL-6) in stimulated macrophages — an innate-immune, anti-inflammatory signal. Thymosin Alpha-1 acts on the adaptive arm: it promotes T-cell maturation and NK-cell activity, tuning the immune system toward a more calibrated response rather than just suppressing it. Two different arms of immunity, not the same lever twice. This pairing is more defensible than the Khavinson family combination because Thymosin Alpha-1 has actual human trial data (see its page — including the honesty note that its most rigorous independent trial was null).
The protocol:: Chonluten 500–1,000 mcg subcutaneously once daily for a ~10-day course, run concurrently with or immediately before/after Thymosin Alpha-1 on its own schedule (commonly 1.5 mg subcutaneously twice weekly).
Outcome:: Reached for in contexts where an immune system is both dysregulated and under-responsive — chronic immune fatigue, post-viral, or general immune support goals. Note the honesty axis on the Thymosin Alpha-1 page — its evidence is real but limited; this stack is still doubly convention.

Reconstitution math

Reconstitution calculator

Calculated for a 1 mL U-100 insulin syringe (100 units/mL).

Peptide per vial

BAC water added

Desired dose

Units per dose

Draw to this mark on a U-100 syringe

Volume per dose: 0.2 mL
Doses per vial: 10
Concentration: 5 mg/mL

One vial lasts

Daily: 10 days
Every other day: 20 days
5×/week: 14 days

Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.

From the studies

Side effects from research

There is no meaningful human safety database for Chonluten. The single confirmed study is an in-vitro cell experiment, which cannot characterise side effects, rare events, or long-term risk in people. Absence of reported harm in a dish is not the same as a demonstrated safety profile.

Because the product is marketed for serious respiratory conditions (COPD, asthma, bronchitis) that it has no trial evidence to treat, the lack of any controlled human data is particularly worth flagging — relying on it in place of proven respiratory care would be a real risk.

Gray-market sourcing, plus the extract-vs-synthetic ambiguity, adds purity and identity risk independent of the peptide. The honest summary: Chonluten's human safety is uncharacterised, not established.

Sources:PMID 35408963

As reported in literature

Research dosing ranges

There is one confirmed study, and it is in a lab dish — shown for reference only. There is no human dose, no approved regimen, and no independent replication. Note what was actually tested: an anti-inflammatory readout in cultured immune cells, with Chonluten as one of five peptides. Nothing about lungs, breathing, or disease was tested. The distance between that and the 'regenerates lung tissue' marketing is the point.

Dose	Route	Model	Outcome	Sources:
In vitro	Cell culture	Human THP-1 monocyte/macrophage cell line, 5-peptide panel (Avolio 2022, Int J Mol Sci)	Chonluten — one of five Khavinson peptides — reportedly reduced LPS-stimulated TNF and IL-6 expression. A generic anti-inflammatory signal in immune cells; not a respiratory or lung result, and a network collaboration rather than independent replication	PMID 35408963

Quick answers

Frequently asked

What is Chonluten?

It is a trade name (also spelled Honluten) for EDG, a synthetic tripeptide (Glu-Asp-Gly) from Vladimir Khavinson's Russian 'Cytogen' line of short peptide bioregulators, marketed as the 'lung' or 'respiratory' peptide. The underlying molecule is well-defined chemically; the respiratory claims are not supported by any study of Chonluten in the lungs.

Does Chonluten regenerate lung tissue or treat COPD/asthma?

There is no evidence that it does. The only confirmed study is an in-vitro experiment in immune cells where it was one of five peptides reducing inflammation markers — not a lung study, not an animal breathing model, and not a human trial. Treat the respiratory claims as unproven vendor marketing.

Is the chemistry real?

The molecule is real: Glu-Asp-Gly is a defined tripeptide in PubChem (CID 194641, also called 'T-34 tripeptide'). But 'Chonluten' itself is not a chemical-database name, and the brand is sold both as this synthetic peptide and as a tissue extract — so vendors are attaching one molecule's identity to two different products.

Is there a known dose?

No. There is no citable, trial-grounded human dose — there are no human trials at all. Any mg amounts, injection cycles or sublingual 'courses' from vendors are unverified convention, not evidence.

Is Chonluten approved or independently validated?

No. It is not approved by any major drug regulator, and the single study is a Khavinson-network in-vitro paper, not an independent replication. Vendor marketing is not evidence of Western or independent validation.

Why is Chonluten in the Immune category if it's marketed as respiratory?

Because the only confirmed published evidence is an anti-inflammatory readout in human immune cells (THP-1 monocytes/macrophages) — not a respiratory model. The marketed respiratory identity is not supported by any Chonluten study in lung tissue, animal breathing models, or human pulmonary trials.

Primary sources

References

PMID 35408963Avolio F, Martinotti S, Khavinson VK, Esposito JE et al., Int J Mol Sci 2022 — five Khavinson peptides (incl. Chonluten) reduced LPS-stimulated TNF and IL-6 in the human THP-1 monocyte/macrophage line (in vitro; Italy–Russia collaboration WITH Khavinson, not independent replication; respiratory thesis not tested)
PubChem CID 194641PubChem record — identity (CID, formula, MW, CAS, InChIKey) for the tripeptide Glu-Asp-Gly. Note: 'Chonluten' is NOT a PubChem synonym; the database name is 'glutamyl-aspartyl-glycine' / 'T-34 tripeptide'

Research use only · Not medical advice · Updated 2026-06-01